Cerebral amyloid angiopathy presenting as a brain mass.

A K Osumi, R D Tien, G J Felsberg and M Rosenbloom

*AJNR Am J Neuroradiol* 1995, 16 (4) 911-915

http://www.ajnr.org/content/16/4/911

This information is current as of October 28, 2023.
Cerebral Amyloid Angiopathy Presenting as a Brain Mass

Alan K. Osumi, Robert D. Tien, Gary J. Felsberg, and Mark Rosenbloom

Summary: The MR images of a patient with cerebral amyloid angiopathy (a localized vascular deposition of amyloid without evidence of systemic amyloidosis) showed an extensive right temporoparietal lobe mass with frontal lobe extension that was slightly hypointense on T1-weighted images and heterogeneously hyperintense on T2-weighted images. No contrast enhancement was identified on MR imaging.

Index terms: Amyloidosis; Arteries, cerebral; Arteries, diseases

Primary intracranial deposition of amyloid is usually seen within neuritic plaques and blood vessel walls without the presence of systemic amyloidosis (1, 2). The deposition of amyloid within the cerebral and meningeal blood vessels walls is called cerebral amyloid angiopathy or congophilic angiopathy (3). The usual neurologic presentation of cerebral amyloid angiopathy is a spontaneous cerebral hemorrhage occurring in an elderly patient with normal blood pressure (4–12). Cerebral amyloid angiopathy presenting as a mass in the brain without the evidence of hemorrhage is unusual (13–16). A case of cerebral amyloid angiopathy is presented with both computed tomographic (CT) and magnetic resonance (MR) findings.

Case Report

A 59-year-old black woman had a medical history of insulin-dependent diabetes mellitus and hypertension. Twenty-nine months before the current admission, the patient was evaluated for left-sided focal seizures that progressed to generalized seizures. Unenhanced CT and MR of the brain were unremarkable (Fig 1). An electroencephalogram showed focal slowing and no active seizure activity. Phenytoin therapy was instituted.

On her current admission, the patient had subacute onset of weakness and severe headaches on the left side. Admission blood pressure was 210/90 mm Hg. Brain CT showed a large, nonenhancing, nonhemorrhagic, low-attenuation mass involving the right temporal, parietal, and parietofrontal white matter with mass effect and a 1-cm right-to-left midline shift (Fig 2). The patient was immediately started on high-dose steroids. Electroencephalography showed right hemisphere slowing consistent with either a postictal state, a mass, or a vascular insult. A postcontrast MR study of the brain with gadolinium ethylenediaminetetraacetic acid showed a nonenhancing, right hemisphere mass with no apparent regions of infarction or hemorrhage (Fig 3). A diagnosis of a low-grade glioma was considered.

Cerebrospinal fluid electrophoresis showed no evidence of oligoclonal bands, and serum electrophoresis only showed hypoalbuminemia at 2.05 g/dL. The patient underwent a stereotactic biopsy. The biopsy returned reactive gliosis and was considered to be nondiagnostic. The patient then underwent a right temporal craniotomy and subtotal resection of the right temporal lobe.

Histology revealed focal deposits within vessels walls of a Congo red staining substance that produced apple green birefringence when viewed under polarized light. This finding was consistent with amyloid deposition within the vessel walls. Vascular deposition of amyloid was present mostly within the leptomeningeal and cortical vessels. No evidence of focal deposition of amyloid was seen within the white or gray matter. Diffuse gliosis and edema was identified within the white matter; however, no evidence of hemorrhage was seen. These histologic findings were diagnosed as a diffuse form of cerebral amyloid angiopathy.

After surgery, the patient remained somnolent and only followed simple commands. High-dose steroids were continued for 3 months without any change in the patient’s mental status. The rectal biopsy, performed to exclude systemic amyloidosis, was normal. No evidence of systemic amyloidosis could be identified. The patient was weaned off steroids, but continued to take phenytoin for seizure activity, which occurred about once a week. The patient’s physical and mental status slowly deteriorated over the next few months. She died 5 months after initial presentation.

Discussion

Amyloid is an eosinophilic, insoluble, extracellular protein that was described by Virchow...
(17). It stains with Congo red and characteristically produces a pathognomonic apple green birefringence under polarized light (18). Electron microscopy shows that amyloid is composed of nonbranching protein fibrils of indeterminate length, but consistently has a diameter between 7.5 and 10 nm (19). These fibrils are arranged in crossed beta pleated sheets, as seen in x-ray diffraction (20, 21). Three parameters are used to identify amyloid in a tissue: (a) positive Congo red staining with apple green birefringence under polarized light, (b) distinct fibrillar ultrastructure on electron microscopy, and (c) crossed beta pleated sheets on x-ray diffraction (22).

Amyloid may be present as a focal deposition, or as part of a systemic disease. Systemic amyloid deposition, known as amyloidosis, is found in patients with gammopathies or plasma cell dyscrasias. Localized amyloid deposition occurring within the media and intima of the arteries and arterioles of the brain and meninges is known as cerebral amyloid angiopathy. Cerebral amyloid angiopathy seems to have slight predilection for the temporal, parietal, and occipital lobes. It principally affects the elderly and tends to increase in prevalence with advancing age (5, 23). There is no significant sex predilection (4, 8, 23). Superficial cortical hemorrhages are the most common finding. The amyloid within the vessel walls presumably leads to either their increased fragility or rupture of microaneurysms.

Cerebral amyloid angiopathy presenting as a focal, nonhemorrhagic mass (13–15) or as multifocal, nonhemorrhagic lesions (16) is rare. It is not part of systemic amyloidosis or of focal intraparenchymal amyloid deposition seen in rare cases of central nervous system amyloidosis.
omas (24–29). The limited follow-up in the reported cases of focal, nonhemorrhagic cerebral amyloid angiopathy ranged from 4 months to 13 years and showed no evidence of growth of the lesion or progression of the presenting neurological deficit (13–15). In these cases, the angiopathy behaved in a benign fashion, although the presenting neurologic deficit persisted.

The CT findings in our case and the other reported cases of focal cerebral amyloid angiopathy are similar (Fig 2). They showed a hypodense mass involving white matter. There was no evidence of hemorrhage or contrast enhancement. The locations of most of the mass lesions of the focal angiopathy were the temporal, temporoparietal, and frontal lobes. A presumed diagnosis of an infiltrating glioma was made in all of the cases of focal cerebral amyloid angiopathy on the basis of CT findings.

MR imaging was performed in our case. The initial conventional T1- and T2-weighted images of the brain were normal when the patient first presented with partial complex seizures (Fig 1). Follow-up T1-weighted MR images 29 months later showed a nonenhancing, slightly hypointense mass involving the right temporoparietal and temporofrontal white matter (Fig 3). The lesion had heterogeneous high sig-
mural intensity on the T2-weighted sequences. No evidence of hemorrhage could be found on the MR images. The MR study, like the CT scan, was compatible with the presumed diagnosis of a low-grade glioma.

The current case in many ways is similar to the previously reported cases, and has two interesting aspects. The first is that the initial MR study showed no demonstrable lesion, even though the patient was symptomatic at that time with partial complex seizures. It can be speculated that the angiopathy developed from an undetected small focus in the right temporal lobe that caused the partial complex seizures into a large mass involving the entire temporoparietal white matter with extension into the frontal white matter during the 29-month period between MR studies.

The second aspect has to do with the histology of the large mass seen on the imaging studies during the latest admission for weakness on the left side. The histology of the resected brain specimen revealed edema and gliosis as the composition of the observed mass. Amyloid depositions within the vascular walls were also identified, but no hemorrhage or amyloid deposition was observed within the white or gray matter. Edema and gliosis of white matter is compatible with the observed MR and CT findings of the mass. Also the fact that no hemorrhage was identified on either CT or MR images is compatible with the observed histologic findings. Loes et al (16) and Gray et al (30) have speculated that the amyloid deposition within the vascular walls may contribute to hypoperfusion to vulnerable areas of white matter. This might account for the high T2 signal abnormality seen on the MR images of this patient and in the patients with cerebral amyloid angiopathy in the study of Loes et al (16).

In conclusion, cerebral amyloid angiopathy is a nonneoplastic, vascular wall deposition of amyloid that usually presents as a focal cortical hemorrhage in the brain, but occasionally presents as a localized mass in the brain without evidence of hemorrhage. Neuroimaging findings are limited to demonstration of a white matter mass. No contrast enhancement or hemorrhage is seen. No single imaging method allows one to distinguish a focal mass of cerebral amyloid angiopathy from other white matter masses of the brain. The differential diagnosis must include primary brain tumors like gliomas. Atypical vascular infarction and inflammatory causes could also be considered. The clinical history should be helpful in sorting out these entities.

References


